[6-(4-chloro-phenylamino)-pyridin-3-yl]-(4-methyl-piperidin-1-yl)-methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [6-(4-chloro-phenylamino)-pyridin-3-yl]-(4-methyl-piperidin-1-yl)-methanone
• 英文别名: (6-(4-Chlorophenylamino)pyridin-3-yl)(3-methylpiperidin-1-yl)methanone；[6-(4-chloroanilino)pyridin-3-yl]-(4-methylpiperidin-1-yl)methanone
• 化学式: C₁₈H₂₀ClN₃O
• 分子量: 329.829
• InChiKey: ARKOFPWBWBXGLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-甲基哌啶 、 6-((4-Chlorophenyl)amino)nicotinic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 乙二醇二甲醚 为溶剂， 反应 6.0h， 生成 [6-(4-chloro-phenylamino)-pyridin-3-yl]-(4-methyl-piperidin-1-yl)-methanone
  参考文献：
  名称：

  Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity

  摘要：

  High throughput screening led to the identification of nicotinamide derivative 2 as a structurally novel mGluR5 antagonist. Optimization of the modular scaffold led to the discovery of 16m, a compound with high affinity for mGluR5 and excellent selectivity over other glutamate receptors. Compound 16m exhibits a favorable PK profile in rats, robust anxiolytic-like effects in three different animal models of fear and anxiety, as well as a good PK/PD correlation. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.001

文献信息

• Organic Compounds
  申请人：Glatthar Ralf

  公开号：US20090005363A1

  公开（公告）日：2009-01-01

  The present invention relates to novel nicotinic acid derivatives, of formula (I) wherein the substituents are defined in the specification, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.

  本发明涉及新的烟酸衍生物，其化学式为（I），其中取代基在规范中定义，其制备方法，其作为药物的用途以及含有它们的药物组合物。
• USES OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Ralf Glatthar

  公开号：US20100041641A1

  公开（公告）日：2010-02-18

  The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.

  本发明涉及使用mGluR调节剂，例如mGluR5调节剂，用于治疗、预防或延缓认知功能障碍的进展。
• USE OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：GLATTHAR Ralf

  公开号：US20120309742A1

  公开（公告）日：2012-12-06

  The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.

  本发明涉及使用mGluR调节剂，例如mGluR5调节剂，用于治疗、预防或延缓认知功能障碍的进展。
• New Uses of metabotropic glutamate receptors
  申请人：Novartis AG

  公开号：EP2272509A1

  公开（公告）日：2011-01-12

  The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.

  本发明涉及使用 mGluR 调节剂（如 mGluR5 调节剂）治疗、预防或延缓认知功能障碍的进展。
• NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：NOVARTIS AG

  公开号：EP2069305A2

  公开（公告）日：2009-06-17